Phase 3 N=421 Efficacy and Safety of Quetiapine Versus Quetiapine Plus Lithium in Bipolar Depression
Acute Bipolar Depression
Primary: Change in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score. — 23.7; 24.3 scores on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=213 Study of the Safety and Efficacy of Golimumab in Chinese Patients With Ankylosing Spondylitis
Ankylosing Spondylitis
Primary: Assessment of Ankylosing Spondylitis Response (ASAS 20) at Week 14 — 26; 53 Participants
Phase 3 N=1,176 Efficacy and Safety of Oral Salmon Calcitonin in Patients With Knee Osteoarthritis
Osteoarthritis
Primary: Joint Space Width (JSW) in the Medial Tibiofemoral Knee Joint in Signal Knee Measured by X-ray After 24 Months. — -0.188; -0.198 mm
Phase 3 N=130 A Primary Care Behavioral Approach for Addressing Childhood Overweight
Obesity
Primary: BMI Z-score(for Gender and Age)at 6-months — -0.129; 0.001 Z-score
Phase 3 N=298 Research Evaluating an Investigational Medication for Erectile Dysfunction - Post-Prostatectomy
Erectile Dysfunction
Primary: Change in Percentage of Sexual Attempts in Which Subjects Are Able to Maintain an Erection of Sufficient Duration to Have Successful Intercourse — 13.9; 28.0; 29.4…
Phase 3 N=390 Research Evaluating an Investigational Medication for Erectile Dysfunction - Diabetic ED (REVIVE-D)
Erectile Dysfunction
Primary: Change in Percentage of Sexual Attempts in Which Subjects Were Able to Maintain an Erection of Sufficient Duration to Have Successful Intercourse — 13.6; 28.7; 34.0…
Phase 3 N=662 Endometrial Safety Study
Postmenopause
Primary: Number of Participants in the DRSP/E2 Group With an Assessment of Endometrial Hyperplasia or Worse at End of Study (EoS) (1 Year of Treatment) — 0 Participants
Phase 3 N=712 Long-Term Safety and Efficacy Study of Avanafil in Men With Erectile Dysfunction
Erectile Dysfunction
Primary: Change in Percentage of Sexual Attempts in Which Subjects Were Able to Maintain an Erection of Sufficient Duration to Have Successful Intercourse. — 54.75 percentage of…
Phase 3 N=646 Research Evaluating an Investigational Medication for Erectile Dysfunction - General ED
Erectile Dysfunction
Primary: Change in Percentage of Sexual Attempts in Which Subjects Were Able to Maintain an Erection of Sufficient Duration to Have Successful Intercourse — 14.1; 27.8; 43.4…
Phase 3 N=198 Effect of a Booster Dose of the Japanese Encephalitis Vaccine IC51
Japanese Encephalitis
Primary: Seroconversion Rate — 98.5 percent
Phase 3 N=750 Immunogenicity and Safety Study of GSK Biologicals' Human Papillomavirus 580299 Vaccine in Healthy Female Subjects
Infections, Papillomavirus
Primary: Geometric Mean Titers (GMTs) for Antibodies Against Human Papillomavirus (HPV)-16/18 Antigens — 18347.1; 5.0; 7960.2; 4.1 EL.U/mL
Phase 3 N=874 Relapse Prevention Study Of Desvenlafaxine Succinate Sustained Release In Outpatients With Major Depressive Disorder
Major Depressive Disorder
Primary: Time to Relapse Following Randomization to the Double-blind (DB) Phase: Estimated Probability (Percent) of Relapse at DB Day 185 — 30.2; 14.3 percent estimated…
Phase 3 N=8,101 Venous Thromboembolic Event (VTE) Prophylaxis in Medically Ill Patients
Venous Thromboembolism
Primary: Percentage of Participants With Composite Endpoint of Venous Thromboembolism [VTE] (Any Deep Vein Thrombosis [DVT], Non Fatal Pulmonary Embolism [PE]) and VTE-related…
Phase 3 N=40 Evaluation of Inter-reader Reliability Using Images From Subjects With Alzheimer's Disease (AD) or Mild Cognitive Impairment (MCI)
Alzheimer's Disease
Primary: Inter-reader Agreement - Median Kappa Statistic — 0.72; 0.70; 0.25; 0.75 median kappa
Phase 3 N=451 A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin's Lymphoma (RATE)
Non-Hodgkin's Lymphoma
Primary: Percentage of Patients Who Developed Grade 3 or 4 Infusion-related Reactions (IRR) Resulting From Faster Infusion of Rituximab During Days 1 and 2 of Cycle 2 — 1.1…